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CLINICAL INVESTIGATIONS
Is There an Association Between Metabolic Syndrome and
Cognitive Function in Very Old Adults? The Newcastle 85+
Study
Stephanie L. Harrison, MSc,* Blossom C. M. Stephan, PhD,* Mario Siervo, PhD,†
Antoneta Granic, PhD,* Karen Davies, PhD,* Keith A. Wesnes, PhD,‡§
Thomas B. L. Kirkwood, PhD,† Louise Robinson, MD,* and Carol Jagger, PhD*
OBJECTIVES: To determine, using data from the New-
castle 85+ Study, whether there is an association between
modern diagnostic criteria for metabolic syndrome (MetS)
and cognitive function in very old adults (≥85) and
whether inflammation, physical activity, or diabetes
mellitus status affects this association.
DESIGN: Longitudinal, population-based cohort study.
SETTING: Newcastle and North Tyneside, United Kingdom.
PARTICIPANTS: Community-dwelling and institutional-
ized men and women recruited through general practices
(N = 845).
MEASUREMENTS: MetS was defined according to the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III) criteria. Cross-sectional and
prospective (up to 5 years of follow-up) associations
between MetS and global cognitive function (assessed
using the Mini-Mental State Examination (MMSE)) and
between MetS and attention and episodic memory
(assessed using the Cognitive Drug Research battery) were
performed.
RESULTS: MetS was not associated with cognitive func-
tion at baseline or cognitive change over time. Lack of
association was not because MetS was predictive of subse-
quent mortality. Of the individual components of the MetS
criteria, high blood pressure was associated with better
cognitive function at baseline (MMSE: b (standard error
(SE)) = 0.716 (0.152), P < .001), and low high-density
lipoprotein cholesterol was associated with poorer global
cognitive function at baseline (MMSE: 0.436 (0.131),
P = .001).
CONCLUSION: The association between MetS and cog-
nitive decline, which has been described in younger popu-
lations (<75), was not apparent in this population of
individuals aged 85 and older at baseline. J Am Geriatr
Soc 2015.
Key words: metabolic syndrome; cohort study; very
old; cognition; aging
Metabolic syndrome (MetS) refers to a group of meta-bolic and vascular disorders that occur simulta-
neously and is frequently defined as having three or more
of the following: high blood pressure, high glucose levels,
large waist circumference, low high-density lipoprotein
cholesterol (HDL-C) levels, and high triglyceride levels.1
An association has been observed between MetS and
dementia, including preclinical dementia,2 but few studies
have examined the link between MetS and cognitive func-
tion more generally, although cross-sectional and longitu-
dinal associations between MetS and poor cognitive
function have been found.3–6 In young-old adults (<75),
each of the individual diagnostic components of MetS has
also been associated with greater risk of cognitive impair-
ment,7 although whether the association between poor
cognitive function and MetS is greater than the sum of its
individual diagnostic components is still unclear.3,5
The one other longitudinal study, the Leiden 85+
Study,8 that has explored the association between MetS
and cognitive decline in very old adults (≥85) found that
participants with MetS had a slower rate of cognitive
decline than those without MetS, but because of data
restrictions, that study used a modified version of the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III) criteria. Body mass index
(BMI) was used instead of waist circumference, and non-
fasting rather than fasting plasma glucose levels were
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measured.8 Thus, whether similar results are found when
MetS is defined using the specific NCEP ATP III criteria,
as originally defined, is not known, so it was explored in
another cohort study of individuals aged 85 and older,
the Newcastle 85+ Study.
The hypothesis was that MetS was associated with a
slower rate of cognitive decline, consistent with the find-
ings from the Leiden 85+ Study, although it was hypothe-
sized that individuals with MetS with high inflammation
or diabetes mellitus may have a greater risk of cognitive
decline as a result of a greater metabolic and vascular load
and accelerated cognitive aging.
The aim of this study was to determine whether there
is an association between MetS and cognitive function in
the Newcastle 85+ cohort using the full version of the
NCEP ATP III criteria. To the knowledge of the authors,
this is the first study to test the association between MetS
and cognitive function in very old adults when mapping
criteria specifically set by NCEP ATP III, without making
any adjustments. Whether levels of inflammation, physical
activity, or diabetes mellitus modify associations was also
examined.
METHODS
Study Population
Participants were from the Newcastle 85+ Study, a popula-
tion-based longitudinal study of health and aging in very
old adults; full details of the study have been published
previously.9,10 In brief, all surviving adults born in 1921,
regardless of health status and place of residence, who
turned 85 in 2006 when the study commenced and were
permanently registered with a participating general prac-
tice in Newcastle-upon-Tyne and North Tyneside (north-
east England) were invited to participate; 845 participants
had baseline (2006–2007) data collected, including infor-
mation from a detailed multidimensional health assessment
interview and review of general practice records. Follow-
up took place at 18 (Phase 2), 36 (Phase 3), and 60 (Phase
4) months. Figure 1 shows the numbers of participants at
each follow-up and how many participants had available
cognitive test scores. Further details of retention in the
Newcastle 85+ Study have been described elsewhere.11 A
trained research nurse conducted all assessments at the
participant’s usual residence (home or institution).
Metabolic Syndrome
MetS was diagnosed using the NCEP ATP III criteria,1
which require that the participant fulfill three or more of
the following five clinical criteria: large waist circumfer-
ence (≥102 cm in men, ≥88 cm in women), high triglyce-
rides (≥1.7 mmol/L (150 mg/dL) or receiving drug
treatment for high triglycerides), low HDL-C
(<1.03 mmol/L (40 mg/dL) in men, <1.3 mmol/L (50 mg/
dL) in women, or receiving drug treatment for low HDL-
C), high blood pressure (≥130 mmHg systolic blood pres-
sure, ≥85 mmHg diastolic blood pressure, or receiving
antihypertensive medication), and high fasting glucose
(≥5.6 mmol/L (100 mg/dL) or receiving drug treatment for
high glucose). MetS status was determined for 92.4%
(n = 781) of the 845 participants seen at baseline.
Cognitive Assessment
Global cognitive function was assessed using the Mini-
Mental State Examination (MMSE),12 which includes
questions based on five domains: orientation, registration,
attention and calculation, recall, and language, with scores
ranging from 0 to 30. The MMSE was administered at
baseline and 36 (Phase 3) and 60 (Phase 4) months.
Phase 2 (18 months from baseline) n=631
PoA n=546, CoA=546, and SI=526
Phase 3 (36 months from baseline) n=484
MMSE n=470
PoA n=406, CoA=406, and SI=394
Deaths n=95
Withdrew and gave approval for use of data n=51 (non-
health reasons n=16; health reasons n=35) 
Activity suspended until phase 4 n=1
Deaths n=135
Withdrew and gave approval for use of data n=88 (non-
health reasons n=53; health reasons n=35)
Baseline n=854*
MMSE n=839
PoA n=729, CoA=732, and SI=712
Phase 4 (60 months from baseline) n=344
MMSE n=331
Deaths n=114
Withdrew and gave approval for use of data n=27 (non-
health reasons n=12; health reasons n=15)
Abbreviations: *The present analysis required data from both the health assessment and review of general practice records 
which was available for 845 participants. MMSE=Mini-Mental State Examination; PoA=Power of Attention; CoA=Continuity 
of Attention; SI=Sensitivity Index for Recognition Ability.
Figure 1. Flowchart of participants at each phase of the Newcastle 85+ Study.
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Attention and episodic memory were measured using
the Cognitive Drug Research (CDR) computerized assess-
ment system, conducted at baseline and 18 (Phase 2) and
36 (Phase 3) months. A test administrator explained each
task to each participant, the task stimuli were presented
on the screen of a laptop computer, and the participant
responded using a two-button (NO/YES) response box.
Although computer literacy is not a requirement of the
CDR, a training session on the CDR battery, with fewer
stimuli, was performed before the assessment to demystify
the process and ensure that participants were comfortable.
The standard time delay between training and assessment
was 1 week.13 Three main tasks measuring response times
were used to examine core aspects of attention: Simple
Reaction Time, which determines alertness, power of con-
centration, and ability to respond rapidly; Choice Reac-
tion Time, which is similar to Simple Reaction Time but
adds stimulus discrimination and response selection; and
the Digit Vigilance Task, which measures sustained atten-
tion, attentiveness, and ability to ignore distractions. Two
composite variables were used from the CDR test results
that were created from the three main attention tasks:
power of attention (PoA), measuring focused attention,
and continuity of attention (CoA), measuring sustained
attention.14
Episodic and declarative memory was assessed using a
word recognition task.15 Using the results from the word
recognition task, a sensitivity index for recognition ability
(SI) (formed by combining correct recognition responses
for original words and correct rejections of new words;
range 0–1) was calculated to determine memory perfor-
mance.
Transformations of Cognitive Test Scores
PoA scores were positively skewed and were therefore log-
arithmically (log10) transformed; CoA and MMSE scores
were negatively skewed and were corrected using the fol-
lowing formula: NEWX = SQRT(K–X), in which K is the
maximum score, and X is the participant’s score. Lower
transformed PoA, CoA, and MMSE scores reflect better
cognitive performance.
Potential Confounding Factors
All multivariable models were adjusted for potential con-
founding factors previously shown in the literature to be
associated with cognitive function or MetS: sociodemo-
graphic factors (sex, years of education, marital status),
health factors (history of stroke, ischemic heart disease,
heart failure), and lifestyle factors (smoking status, current
alcohol consumption).
Inflammatory Marker
C-reactive protein (CRP) was measured from a fasting
baseline blood sample drawn between 7:00 a.m. and 10:30
a.m. and delivered to the laboratory (vein to laboratory) in
less than 1 hour, where it was analyzed using a high-sensi-
tivity assay, with high inflammation defined as greater
than the median (2.6 mg/L) CRP level and low inflamma-
tion as the median CRP level or less.
Statistical Analysis
Baseline characteristics of participants with and without
MetS were compared using chi-square tests for categorical
variables and Mann–Whitney U-tests for nonnormally dis-
tributed continuous variables. Nonnormally distributed
data were presented as medians and interquartile ranges
(IQRs). Participants lost to follow-up were also compared
with those still in the study 5 years after baseline using
Mann-Whitney U-tests for nonnormally distributed contin-
uous data and chi-square tests for categorical data. All
reported P-values are two-tailed, and statistical significance
was set at P < .05.
SPSS Statistics 19.0 (IBM Corp., Armonk, NY) mixed
models were used with a restricted maximum likelihood
method using a first-order autoregressive covariance
matrix to examine parameter estimates (b) with standard
errors (SEs). Linear mixed models were used to examine
change in attention and episodic memory (CDR cognitive
tasks) over 36 months (baseline to Phase 3) and in global
cognitive functioning (MMSE) over 60 months (baseline to
Phase 4). To compare results with those of the Leiden 85+
Study,8 the first linear mixed model included MetS status
at baseline, time, an interaction between MetS and time,
and all potential confounding factors. The parameter esti-
mate for MetS shows the cross-sectional effect of MetS on
cognitive function at baseline and is presented as the cross-
sectional effect. The parameter estimate for time shows the
change in cognition scores over time for the whole popula-
tion and is presented as change over time (MMSE, 5 years;
CDR, 3 years). The parameter estimate for the interaction
between MetS and time shows the change in cognition
over time attributable to MetS and is presented as change
due to MetS. These models were then repeated for the
number of MetS components (0–5) and then for each indi-
vidual MetS component with change in cognitive function
over time.
Analyses were also performed after stratifying partici-
pants according to level of inflammation (categorized as
high (>2.6 mg/L CRP) vs low (≤2.6 mg/L CRP)), physical
activity (self-reported, question based on sporting activities,
gardening, housework, do it yourself work, and walking,
categorized as high (≥3 times per week) vs low to medium
(<3 times per week)), and diabetes mellitus status at baseline
(with presence of diabetes mellitus defined according to
review of general practice health records or as a fasting
glucose level ≥7.0 mmol/L, as defined by the World Health
Organization classification).16 Whether greater risk of mor-
tality associated with MetS might mask the relationship
between MetS and cognitive decline was examined using
Cox proportional hazard models. Hazard ratios (HRs) for
mortality were estimated with MetS first adjusted for poten-
tial confounding factors (as detailed above) and then further
adjusted for baseline cognitive function.
RESULTS
Baseline Characteristics of Participants According to
MetS Status
The baseline prevalence of MetS was 27.4% (95% confi-
dence interval (CI) = 24.3–30.5%; n = 214). Of those with
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MetS, 68.7% (n = 147) met three of the NCEP ATP III
criteria, 24.8% (n = 53) met four criteria, and 6.5%
(n = 14) met five criteria. The most common MetS crite-
rion met in the whole population was high blood pressure
(94.4%), followed by large waist circumference (38.3%),
high triglycerides (28.5%), high fasting glucose (29.7%),
and low HDL-C (8.2%).
The baseline characteristics of the sample included in
this analysis are shown according to MetS status in
Table 1. Participants with MetS were significantly more
likely to be female (P = .02) and to have diabetes mellitus
(P < .001), higher CRP levels (P < .001), and a history of
ischemic heart disease (P < .001) and heart failure
(P = .03). There were no significant differences found
between participants with and without MetS in level of
education, physical activity, smoking status, current alco-
hol consumption, marital status, living arrangement,
depressive symptoms, or history of stroke. Table 2 shows
the cognitive scores of participants at baseline and each
follow-up phase.
MetS and Global Cognitive Function: MMSE
There was no cross-sectional association between MetS
and global cognitive function (Table 3). When examining
the individual components of MetS, individuals with high
blood pressure had higher baseline MMSE scores (b (SE) =
0.716 (0.152), P < .001), and individuals with low
HDL-C levels had lower baseline MMSE scores (b (SE) =
0.436 (0.131), P = .001).
Table 1. Baseline Characteristics of Participants in the Newcastle 85+ Study According to Metabolic Syndrome
(MetS) Status
Characteristic All Participants, N = 845 MetS, n = 214 No MetS, n = 567 P-Value
Female, n (%) 526 (62.2) 145 (67.8) 331 (58.4) .02
Education, years, n (%)
0–9 534 (64.4) 139 (66.2) 354 (63.2) .41
10–11 189 (22.8) 50 (23.8) 130 (23.2)
≥12 106 (12.8) 21 (10.0) 76 (13.6)
High blood pressure, n (%)a 781 (94.4) 212 (99.1) 519 (93.0) <.001
High glycemia, n (%)b 232 (29.7) 141 (65.9) 90 (15.9) <.001
High triglycerides, n (%)c 222 (28.5) 152 (71.4) 70 (12.4) <.001
Low high-density lipoprotein cholesterol, n (%)d 60 (8.2) 51 (26.4) 9 (1.7) <.001
High waist circumference, n (%)e 291 (38.3) 167 (81.1) 110 (21.1) <.001
Physical activity, n (%)
Low 189 (23.3) 51 (23.9) 122 (21.7) .18
Moderate 349 (43.0) 99 (46.5) 234 (41.6)
High 274 (33.7) 63 (29.6) 206 (36.7)
Smoking status, n (%)
Never smoked 301 (38.0) 72 (33.6) 200 (38.1) .38
Current or former smoker 491 (62.0) 136 (65.4) 325 (61.9)
Current alcohol drinker 488 (59.5) 131 (61.5) 341 (60.5) .79
Diabetes mellitus, n (%) 211 (25.0) 94 (43.9) 53 (9.4) <.001
History of stroke, n (%) 114 (13.5) 26 (12.1) 80 (14.1) .48
History of ischemic heart disease, n (%) 278 (32.9) 94 (43.9) 167 (29.5) <.001
History of heart failure, n (%) 100 (11.8) 34 (15.9) 58 (10.2) .03
C-reactive protein, mg/L, median (interquartile range) 2.6 (4.8) 3.3 (6.0) 2.3 (4.5) <.001
a Systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or drug treatment.
b Fasting glucose ≥5.6 mmol/L or drug treatment.
c ≥1.7 mmol/L or drug treatment.
d <1.03 mmol/L in men, <1.3 mmol/L in women, or drug treatment.
e ≥102 cm in men, ≥88 cm in women.
Table 2. Baseline and Follow-Up Phase Cognitive Test
Results for the Newcastle 85+ Participants According
to Metabolic Syndrome (MetS) Status
Cognitive Test
Baseline Follow-Up 1 Follow-Up 2
Median (Interquartile Range)
Global cognition (Mini-Mental State Examination (range 0–30))a
All participants 28.0 (4.0) 27.0 (5.0) 27.0 (6.0)
MetS 28.0 (4.0) 27.0 (5.0) 27.0 (5.0)
No MetS 28.0 (4.0) 27.0 (5.0) 27.0 (5.0)
Focused attention (power of attention, ms)b,c
All participants 1,492.1 (358.8) 1,535.2 (344.2) 1,547.1 (354.7)
MetS 1,511.4 (397.4) 1,603.7 (453.1) 1,558.2 (387.7)
No MetS 1,479.0 (335.7) 1,515.7 (330.8) 1,540.1 (339.2)
Sustained attention (continuity of attention, arbitrary units)b,d
All participants 54.0 (8.0) 54.0 (8.0) 54.0 (8.0)
MetS 54.0 (9.0) 54.0 (8.0) 55.0 (10.0)
No MetS 54.0 (7.0) 54.0 (7.0) 54.0 (7.0)
Episodic memory (sensitivity index for recognition ability (range 0–1))b
All participants 0.60 (0.28) 0.56 (0.33) 0.60 (0.33)
MetS 0.60 (0.27) 0.56 (0.29) 0.60 (0.32)
No MetS 0.60 (0.32) 0.56 (0.36) 0.60 (0.33)
a Follow-up 1 was at 36 months; follow-up 2 was at 60 months.
b Follow-up 1 was at 18 months; follow-up 2 was at 36 months.
c Sum of simple reaction time, choice reaction time, and digit vigilance
task (range in this population, 1,061.0–10,892.9).
d Choice reaction time accurate responses 9 0.30 + digit vigilance task
accurate responses 9 0.30–digit vigilance task false alarms (range in this
population, 13 to 60).
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Of the 839 participants who completed the MMSE at
baseline, 57.0% (n = 478) were reassessed on the MMSE
at one or more of the follow-up phases. Participants who
were lost to follow-up were more likely to have more
depressive symptoms (P = .01), to live in an institution
(P < .001), to have high levels of inflammation (P = .01),
and to be diagnosed with dementia (P < .001) than those
with at least one follow-up MMSE assessment. MetS at
baseline was not associated with loss to follow-up
(P = .65). There was also no significant difference in num-
ber of MetS components between those lost to follow-up
and those included (P = .10). Although there was a signifi-
cant decline in MMSE score over time (b (SE) = 0.326
(0.048), P < .001), neither MetS nor the individual MetS
components were associated with changes in MMSE scores
(Table 3).
Stratification of MMSE Results According to
Inflammation, Physical Activity, and Diabetes Mellitus
There was no association between MetS and MMSE score
over time when the results were stratified according to
Table 3. Effect of Metabolic Syndrome (MetS) and MetS Components on Global Cognition over 60 Months and
Attention and Episodic Memory over 36 Months
Cognitive Test
Cross-Sectional Effecta Change over Timeb Change Due to MetSc
b (SE) P-Value
Global cognition (MMSE)
MetSd 0.106 (0.076) .16 0.326 (0.048) <.001 0.026 (0.093) .78
Per extra MetS component 0.001 (0.077) .97 0.286 (0.090) .001 0.016 (0.040) .69
MetS components
High BPe 0.716 (0.152) <.001 0.323 (0.042) <.001 0.077 (0.225) .73
High glycemiaf 0.075 (0.073) .31 0.287 (0.049) <.001 0.104 (0.091) .25
High TGg 0.050 (0.075) .51 0.323 (0.049) <.001 0.006 (0.090) .94
Low HDL-Ch 0.436 (0.131) .001 0.320 (0.043) <.001 0.019 (0.190) .92
High WCi 0.024 (0.070) .74 0.298 (0.053) <.001 0.040 (0.083) .63
Focused attention (PoA)
MetSd 0.008 (0.007) .24 0.026 (0.004) <.001 0.001 (0.007) .91
Per extra MetS component 0.002 (0.002) .41 0.028 (0.005) <.001 0.001 (0.002) .73
MetS components
High BPe 0.025 (0.014) .08 0.029 (0.015) .06 0.003 (0.016) .83
High glycemiaf 0.006 (0.006) .34 0.022 (0.004) <.001 0.014 (0.007) .05
High TGg 0.005 (0.007) .45 0.028 (0.004) <.001 0.006 (0.007) .40
Low HDL-Ch 0.022 (0.012) .07 0.027 (0.003) <.001 0.009 (0.014) .54
High WCi 0.012 (0.006) .06 0.026 (0.004) <.001 0.001 (0.007) .82
Sustained attention (CoA)
MetSd 0.049 (0.084) .56 0.143 (0.046) .002 0.097 (0.089) .27
Per extra MetS component 0.044 (0.034) .20 0.165 (0.069) .002 0.025 (0.030) .40
MetS components
High BPe 0.417 (0.175) .02 0.126 (0.194) .52 0.015 (0.198) .94
High glycemiaf 0.059 (0.081) .47 0.104 (0.047) .03 0.045 (0.087) .60
High TGg 0.077 (0.083) .35 0.127 (0.047) .01 0.036 (0.087) .68
Low HDL-Ch 0.153 (0.151) .31 0.124 (0.042) .003 0.196 (0.176) .27
High WCi 0.013 (0.078) .86 0.105 (0.051) .04 0.014 (0.081) .87
Episodic memory (SI)
MetSd 0.010 (0.015) .52 0.018 (0.008) .02 0.016 (0.015) .30
Per extra MetS component 0.006 (0.006) .30 0.019 (0.013) .14 0.002 (0.006) .79
MetS components
High BPe 0.136 (0.031) <.001 0.007 (0.337) .81 0.032 (0.034) .36
High glycemiaf 0.015 (0.015) .30 0.018 (0.008) .03 0.014 (0.015) .35
High TGg 0.008 (0.015) .61 0.027 (0.008) .001 0.015 (0.015) .31
Low HDL-Ch 0.001 (0.027) .97 0.024 (0.007) .001 0.013 (0.030) .66
High WCi 0.011 (0.014) .45 0.021 (0.009) .02 0.004 (0.014) .76
Models adjusted for sex; education; smoking status; alcohol consumption; marital status; and history of stroke, ischemic heart disease, and heart failure.
For Mini-Mental State Examination (MMSE), power of attention (PoA), and continuity of attention (CoA), scores are transformed, and higher scores
reflect worse performance.
a Cross-sectional effect of MetS (or number of components or each component) on cognitive function at baseline across the population.
b Effect of time across the population over 60 months for MMSE and 36 months for PoA, CoA, and sensitivity index for recognition ability (SI) scores.
c Change over time attributable to MetS (or number of components or each component).
d Reference is the group without MetS or without the component.
e Systolic blood pressure (BP) ≥130 mmHg, diastolic BP ≥85 mm Hg, or drug treatment.
f Fasting glucose ≥5.6 mmol/L or drug treatment.
g Triglycerides (TG) ≥1.7 mmol/L or drug treatment.
h High-density lipoprotein cholesterol (HDL-C) <1.03 mmol/L in men, <1.3 mmol/L in women, or drug treatment.
i Waist circumference (WC) ≥102 cm in men, ≥88 cm in women.
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inflammation level (Table 4) or diabetes mellitus status
(data not shown). In contrast, MetS was associated with
poorer global cognitive performance at baseline in individ-
uals with low levels of physical activity than in those with
high levels (b (SE) = 0.223 (0.101), P = .03), although this
was not replicated in the longitudinal analysis.
MetS and Attention and Memory: CDR (PoA, CoA,
and SI) Measures
The cross-sectional results showed no significant differ-
ences between those with and without MetS on any of the
CDR scores (Table 3). Examination of each individual
MetS component found that higher blood pressure at
baseline was associated with better attention (CoA: b
(SE) = 0.417 (0.175), P = .02) and episodic memory
performance (b (SE) = 0.136 (0.031), P < .001) than lower
blood pressure.
Over 36 months, there was a significant decline in
focused attention (PoA: b (SE) = 0.026 (0.004), P < .001),
sustained attention (CoA: b (SE) = 0.143 (0.046),
P = .002), and episodic memory (b (SE) = 0.018 (0.008),
P = .02) in the whole population. Similar to the MMSE
results, there was no evidence of an association between
MetS and change in any of the CDR cognitive measures
over time. Stratification of CDR results according to
inflammation, physical activity, and diabetes mellitus sta-
tus did not yield any significant results (Table 4).
Sensitivity Analyses
Because previous studies have found no association
between MetS and cognitive decline in healthy older adults
and less decline in individuals with Alzheimer’s disease,17
74 (8.8%) participants with dementia at baseline (defined
from review of general practice records) were excluded
and the analyses repeated, with little change in the results.
Similarly, people with any cognitive impairment at base-
line (two sets of analyses: excluding those with MMSE
≤ 25 and then MMSE ≤24) were also excluded, but again
this did not affect the results (data not shown).
Further sensitivity analyses were conducted, including
changing the definition of hypertension because of the
higher proportion (>85%) fulfilling NCEP ATP III criteria
for hypertension (e.g., tertiles and new normal blood pres-
sure recommendations from the Eighth Joint National Com-
mittee (JNC8) of less than 150/90 mmHg for those aged
≥6018 instead of ≥130 mmHg systolic blood pressure,
≥85 mmHg diastolic blood pressure, or receiving antihyper-
tensive medication) and using glycosylated hemoglobin
(cutoff 7%) instead of fasting glucose to define diabetes
mellitus. These adjustments did not change the cross-sec-
tional or longitudinal findings (data not shown).
MetS and Mortality
Using Cox proportional hazard models with adjustment
for sex, education, smoking status, alcohol consumption,
marital status, history of stroke, ischemic heart disease,
and heart failure, MetS was not found to be associated
with mortality (HR = 1.01, 95% CI = 0.82–1.25, P = .92).
Adding cognitive impairment at baseline to the model did
not change this result (HR = 0.99, 95% CI = 0.80–1.23,
P = .95).
DISCUSSION
This prospective cohort study of adults aged 85 and older
found that MetS was not associated with cognitive perfor-
mance at baseline or over time, although with regard to
Table 4. Effect of Metabolic Syndrome (MetS) on Global Cognition over 60 Months and Attention and Episodic
Memory over 36 Months According to Level of Inflammation
Cognitive Test
Participants with High
Inflammationa
Participants with
Low Inflammationb
b (SE) P
Global cognition (Mini-Mental State Examination)c
Cross-sectional effect of MetS on cognitive function at baseline across the population 0.092 (0.107) .39 0.106 (0.759) .16
Effect of time across the population over 60 months 0.341 (0.079) <.001 0.326 (0.048) <.001
Change over time attributable to MetS 0.154 (0.135) .26 0.026 (0.092) .78
Focused attention (power of attention)
Cross-sectional effect of MetS on cognitive function at baseline across the population 0.001 (0.009) .87 0.019 (0.010) .07
Effect of time across the population over 36 months 0.212 (0.006) <.001 0.029 (0.005) <.001
Change over time attributable to MetS 0.003 (0.010) .79 0.003 (0.107) .78
Sustained attention (continuity of attention)
Cross-sectional effect of MetS on cognitive function at baseline across the population 0.070 (0.114) .54 0.227 (0.129) .08
Effect of time across the population over 36 months 0.165 (0.072) .02 0.134 (0.059) .03
Change over time attributable to MetS 0.128 (0.124) .30 0.069 (0.132) .60
Memory (sensitivity index for recognition ability)
Cross-sectional effect of MetS on cognitive function at baseline across the population 0.029 (0.020) .16 0.012 (0.024) .61
Effect of time across the population over 36 months 0.012 (0.012) .32 0.023 (0.011) .03
Change over time attributable to MetS 0.028 (0.021) .18 0.011 (0.023) .66
Models adjusted for sex; education; smoking status; alcohol consumption; marital status; and history of stroke, ischemic heart disease, and heart failure.
a >Median (2.6 mg/L) C-reactive protein (CRP) level.
b ≤Median CRP level.
c Lower score indicates better performance.
6 HARRISON ET AL. 2015 JAGS
the individual MetS components, high blood pressure was
found to be associated with better baseline cognitive per-
formance, and low HDL-C was associated with poorer
baseline cognitive performance. Furthermore, MetS was
associated with poorer baseline cognitive performance in
participants with lower levels of physical activity.
The main strengths of the study include the use of the
prospective Newcastle 85+ data and the representativeness
of the participants. Only one previous study has examined
MetS and longitudinal changes in cognitive function in
very old adults,8 but it did not fulfill the exact NCEP ATP
III criteria for MetS (e.g., measurements of fasting glucose
levels and waist circumference were not collected), which
was achieved in the Newcastle 85+ Study. Tests of
whether inflammation level, physical activity, or diabetes
mellitus status affected the association between MetS and
cognitive performance had not been conducted before in
this age group. There are some limitations. A lower preva-
lence of MetS was found in the Newcastle 85+ sample
than in the previous study. This may have reduced the
ability of this study to find significant associations between
MetS and cognitive function. Furthermore, generalization
of the findings may be limited to similar populations (aged
≥85 and white).
In previous longitudinal studies, results have been
mixed. A positive association between MetS and poorer
cognitive function over time has been observed.19–29 Gen-
erally, where longitudinal associations have been found,
participants have been younger (highest mean age 75).20
Other longitudinal studies have found no association
between MetS and cognitive function.17,30,31 One of these
studies was similar in design to this study, being con-
ducted with participants aged 80 and older (mean age 85)
and including measures for global cognition, memory and
executive function.30 Furthermore, the Leiden 85+ Study
found MetS to be associated with decelerated cognitive
function on measures of global cognition function
(MMSE), attention and processing speed, but no associa-
tion was found for memory,8 although as noted above,
that study mapped MetS using modified NCEP ATP III
criteria and also recorded a higher prevalence of MetS
(42.2%) than in the current study (27.4%). A recent study
of Taiwanese men aged 75 and older (mean age 82.4) also
found MetS to be significantly associated with lower risk
of global cognitive decline over 1 year and found a preva-
lence of MetS (22.5%) similar to that found in the current
study,32 although this was based on a version of the
NCEP ATP III criteria modified for Chinese men. Age dif-
ferences seen in the risk of cognitive decline associated
with MetS may reflect a survivor bias, such that older par-
ticipants may represent healthy survivors who are not sus-
ceptible to the potentially harmful effect of MetS on
cognition.8 Furthermore, the development of cognitive
impairment may lead to a lower risk of certain compo-
nents of MetS and therefore of MetS overall. For example,
smaller waist circumference may be due to difficulties eat-
ing, or lower blood pressure may be due to underlying
dementia pathology.30
Methodological differences and heterogeneity of the
different populations studied may explain inconsistencies
in the results. Studies differ widely in the assessment
used for cognitive function, age of participants, and
classification criteria for MetS. Furthermore, no previous
study has used the CDR assessment system (episodic
memory and attention tasks). The CDR assessment sys-
tem has been well validated in previous studies with
older individuals33 and has been found to have high sen-
sitivity in tracking changes in attention and memory
over time.34
The current investigation of the individual MetS com-
ponents identified a cross-sectional association between
high blood pressure and better performance on sustained
attention, episodic memory, and global cognition at base-
line. This conflicts with other studies that have reported a
greater risk of cognitive impairment in individuals with
hypertension,3,6,7 although age may be an effect modifier,
because these studies were conducted in younger popula-
tions. A study examining blood pressure and cognitive
function over a wide age range found high blood pressure
to be associated with greater risk of cognitive impairment
in individuals younger than 75, but high blood pressure
was associated with better cognitive function in older par-
ticipants, and this association was strongest in those aged
85 and older.35 There was a high prevalence of high blood
pressure according to the NCEP ATP III criteria in this
cohort (94.4%), which demonstrates the difficulty in dis-
criminating between individuals when applying the current
definition of MetS to this age group, but modifying criteria
to use less-strict cutoffs18 did not change the results. In
contrast, low HDL-C was associated with lower MMSE
scores at baseline, consistent with previous studies that
have reported that lower HDL-C is associated with greater
risk of cognitive impairment.3,7,17,23 The Leiden 85+ Study
found an association between low HDL-C and lower base-
line MMSE scores but, similar to the current study, did
not find a longitudinal effect.8
The lack of an association between MetS overall and
cognitive function may be due to individual components
of MetS working in opposing directions (e.g., low HDL-C
may be harmful, whereas high blood pressure may be
beneficial in this age group). This highlights the impor-
tance of examining the individual components of MetS
when assessing associations between MetS and cognition,
particularly in very old adults. This adds to other evi-
dence that clustering of risk factors in older populations
is problematic.5,8 Furthermore, MetS as a construct is
currently under debate and may be replaced by newer
integrated risk models of cardiovascular health such as
“Life’s Simple 7,” proposed by the American Heart
Association.36
The timing of the assessment of MetS is important,
and a recent metaanalysis found MetS to be associated
with cognitive decline in subjects younger than 70,
whereas the association was not significant for older par-
ticipants.37 Investigations into this effect are needed to
determine whether this is due to a survivor effect or
whether MetS or any of the MetS components offer pro-
tective biological mechanisms in very old adults. Previous
work has suggested that, for very old adults, MetS or cer-
tain components of MetS (e.g., obesity) could offer protec-
tion against cognitive decline. Obesity has been associated
with greater risk of dementia at midlife, but the associa-
tion appears to be reversed in late life,38 perhaps through
biological mechanisms such as insulin resistance39,40 or
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because, for older adults, being underweight is an indica-
tion of poor health, but further research is needed to
understand the etiology of the null or potentially reverse
effect of MetS on cognitive decline seen in very old adults.
Furthermore, the current definition of MetS may not be
appropriate for very old adults, and the cutoff values for
each of the MetS components may need to be revised in
order for a diagnosis of MetS to be meaningful in individ-
uals in this age group.8
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